Integra LifeSciences Holdings Corporation (IART): Price and Financial Metrics


Integra LifeSciences Holdings Corporation (IART): $55.00

0.97 (+1.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IART POWR Grades


  • Value is the dimension where IART ranks best; there it ranks ahead of 83.56% of US stocks.
  • The strongest trend for IART is in Growth, which has been heading down over the past 179 days.
  • IART ranks lowest in Momentum; there it ranks in the 16th percentile.

IART Stock Summary

  • Integra Lifesciences Holdings Corp's market capitalization of $5,558,137,180 is ahead of 73.38% of US-listed equities.
  • IART's current price/earnings ratio is 32.87, which is higher than 74.66% of US stocks with positive earnings.
  • The volatility of Integra Lifesciences Holdings Corp's share price is greater than that of only 6.64% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Integra Lifesciences Holdings Corp, a group of peers worth examining would be PNR, AGRX, MYO, LPTH, and MYGN.
  • IART's SEC filings can be seen here. And to visit Integra Lifesciences Holdings Corp's official web site, go to www.integralife.com.

IART Valuation Summary

  • In comparison to the median Healthcare stock, IART's price/sales ratio is 63% lower, now standing at 4.2.
  • IART's price/earnings ratio has moved up 152.8 over the prior 243 months.
  • IART's EV/EBIT ratio has moved up 193.8 over the prior 243 months.

Below are key valuation metrics over time for IART.

Stock Date P/S P/B P/E EV/EBIT
IART 2021-08-31 4.2 4.0 31.0 29.7
IART 2021-08-30 4.1 3.9 30.1 29.0
IART 2021-08-27 4.1 3.9 30.1 29.0
IART 2021-08-26 4.0 3.9 29.7 28.7
IART 2021-08-25 4.1 3.9 30.2 29.1
IART 2021-08-24 4.1 3.9 30.1 29.0

IART Growth Metrics

    The 2 year price growth rate now stands at -14.73%.
  • Its 5 year net income to common stockholders growth rate is now at 10541.18%.
  • The 5 year net cashflow from operations growth rate now stands at 171.55%.
Over the past 34 months, IART's revenue has gone up $67,399,000.

The table below shows IART's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,542.448 312.427 169.075
2021-09-30 1,525.571 323.412 216.435
2021-06-30 1,508.942 310.272 205.543
2021-03-31 1,377.615 252.099 170.106
2020-12-31 1,371.868 203.832 133.892
2020-09-30 1,378.348 212.754 56.467

IART's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IART has a Quality Grade of C, ranking ahead of 70.12% of graded US stocks.
  • IART's asset turnover comes in at 0.411 -- ranking 114th of 186 Medical Equipment stocks.
  • XENT, ALGN, and CODX are the stocks whose asset turnover ratios are most correlated with IART.

The table below shows IART's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.411 0.614 0.104
2021-06-30 0.416 0.616 0.103
2021-03-31 0.388 0.613 0.086
2020-12-31 0.395 0.620 0.065
2020-09-30 0.406 0.620 0.060
2020-06-30 0.411 0.617 0.030

IART Price Target

For more insight on analysts targets of IART, see our IART price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $77.70 Average Broker Recommendation 1.75 (Moderate Buy)

IART Stock Price Chart Interactive Chart >

Price chart for IART

IART Price/Volume Stats

Current price $55.00 52-week high $76.70
Prev. close $54.03 52-week low $53.57
Day low $53.79 Volume 423,800
Day high $55.28 Avg. volume 466,366
50-day MA $58.95 Dividend yield N/A
200-day MA $64.82 Market Cap 4.57B

Integra LifeSciences Holdings Corporation (IART) Company Bio


Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.


IART Latest News Stream


Event/Time News Detail
Loading, please wait...

IART Latest Social Stream


Loading social stream, please wait...

View Full IART Social Stream

Latest IART News From Around the Web

Below are the latest news stories about Integra Lifesciences Holdings Corp that investors may wish to consider to help them evaluate IART as an investment opportunity.

Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops

Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.

Yahoo | February 24, 2022

Integra LifeSciences Holdings Non-GAAP EPS of $0.84 in-line, revenue of $405.5M beats by $2.09M

Integra LifeSciences Holdings press release (NASDAQ:IART): Q4 Non-GAAP EPS of $0.84 in-line. Revenue of $405.5M (+4.3% Y/Y) beats by $2.09M. For the first quarter 2022, the Company expects reported revenues in the range of $357 million to $365 million vs. consensus of $378.84M, representing reported growth of approximately -1% to...

Seeking Alpha | February 23, 2022

Integra LifeSciences (IART) Q4 Earnings and Revenues Surpass Estimates

Integra (IART) delivered earnings and revenue surprises of 1.20% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Integra LifeSciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides 2022 Financial Guidance

PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2021, consistent with its preliminary revenue results announced on January 11, 2022. Fourth Quarter 2021 Reported revenues were $405.5 million, representing an increase of 4.3% on a reported basis and an increase of 8.3% on an organic basis compared to the fourth quarter 2020. GAAP earnings per diluted

Yahoo | February 23, 2022

Should You Investigate Integra LifeSciences Holdings Corporation (NASDAQ:IART) At US$65.45?

Integra LifeSciences Holdings Corporation ( NASDAQ:IART ), is not the largest company out there, but it received a lot...

Yahoo | February 15, 2022

Read More 'IART' Stories Here

IART Price Returns

1-mo -11.05%
3-mo -17.32%
6-mo -19.60%
1-year -21.32%
3-year -0.15%
5-year 1.68%
YTD -17.90%
2021 3.19%
2020 11.39%
2019 29.22%
2018 -5.77%
2017 11.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4803 seconds.